Dissecting the ribosomal inhibition mechanism of a new ketolide carrying an alkyl-aryl group at C-13 of its lactone ring

International Journal of Antimicrobial Agents

Volumn 35, Issue 3, 2010, Pages 235-239

  Krokidis, Marios G ^a   Kostopoulou, Ourania N ^a   Kalpaxis, Dimitrios L ^a   Dinos, George P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Antibiotics; Coupled transcription translation system; Ketolides; Kosan 1325; Macrolides; Slow binding inhibitors

Indexed keywords

ALKYL GROUP; CARBON; CETHROMYCIN; ERYTHROMYCIN; K 1325; KETOLIDE; KOSAN 1325; LACTONE; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ESCHERICHIA COLI; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROKARYOTE; PROTEIN SYNTHESIS INHIBITION; RIBOSOME; RNA TRANSLATION;

ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; HUMANS; KETOLIDES; KINETICS; MOLECULAR STRUCTURE; PROTEIN BIOSYNTHESIS; RIBOSOMES;

EID: 73549101939     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.11.002     Document Type: Article

References (22)

1. Omura S. Macrolide antibiotics: chemistry, biology and practice (2002), Academic Press, Orlando, FL
2. Ackermann G., and Rodloff A.C. Drugs of the 21st century: telithromycin (HMR 3647)-the first ketolide. J Antimicrob Chemother 51 (2003) 497-511
3. Hammerschlag M.R., and Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 17 (2008) 387-400
4. Katz L., and Ashley G.W. Translation and protein synthesis: macrolides. Chem Rev 105 (2005) 499-528
5. Bailey M., Chettiath T., and Mankin A.S. Induction of erm(C) expression by noninducing antibiotics. Antimicrob Agents Chemother 52 (2008) 866-874
6. Kouvela E.C., Kalpaxis D.L., Wilson D.N., and Dinos G.P. Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity. Antimicrob Agents Chemother 53 (2009) 1411-1419
7. Dinos G., Synetos D., and Coutsogeorgopoulos C. Interaction between the antibiotic spiramycin and a ribosomal complex active in peptide bond formation. Biochemistry 32 (1993) 10638-10647
8. Karahalios P., Kalpaxis D., Fu H., Katz L., Wilson D., and Dinos G. On the mechanism of action of 9-O-arylalkyloxime derivatives of 6-O-mycaminosyltylonolide, a new class of 16-membered macrolide antibiotics. Mol Pharmacol 70 (2006) 1271-1280
9. Blaha G., Stelzl U., Spahn C.M.T., Agrawal R.K., Frank J., and Nierhaus K.H. Preparation of functional ribosomal complexes and the effect of buffer conditions on tRNA positions observed by cryoelectron microscopy. Methods Enzymol 317 (2000) 292-309
10. Dinos G., Wilson D., Teraoka Y., Szafrarski W., Fucini P., Kalpaxis D., et al. Dissecting the ribosomal inhibition mechanisms of edeine and pactamycin: the universally conserved residues G693 and C795 regulate P-site tRNA binding. Mol Cell 13 (2004) 113-124
11. Dinos G., and Kalpaxis D. Kinetic studies on the interaction between a ribosomal complex active in peptide bond formation and the macrolide antibiotics tylosin and erythromycin. Biochemistry 39 (2001) 11621-11628
12. Iskakova M.B., Szaflarski W., Dreyfus M., Remme J., and Nierhaus K.H. Troubleshooting coupled in vitro transcription-translation system derived from Escherichia coli cells: synthesis of high-yield fully active proteins. Nucleic Acids Res 34 (2006) e135
13. Synetos D., and Coutsogeorgopoulos C. Studies on the catalytic rate constant of ribosomal peptidyltransferase. Biochim Biophys Acta 923 (1987) 275-285
14. Hermann T. Drugs targeting the ribosome. Curr Opin Struct Biol 15 (2005) 355-366
15. Shlaes D.M., and Moellering R.C. Telithromycin and the FDA: implications for the future. Lancet Infect Dis 8 (2008) 83-85
16. Morrison J.F., and Walsh C. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61 (1988) 201-301
17. Erion M.D., and Walsh C.T. 1-Aminocyclopropanephosphonate: time-dependent inactivation of 1-aminocyclopropanecarboxylate deaminase and Bacillus stearothermophilus alanine racemase by slow dissociation behavior. Biochemistry 26 (1987) 3417-3425
18. Vester B., and Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 45 (2001) 1-12
19. Wilson D.N., Harms J.M., Nierhaus K.H., Schluenzen F., and Fucini P. Species-specific antibiotic-ribosome interactions: implications for drug development. Biol Chem 386 (2005) 1239-1252
20. Schlunzen F., Harms J., Franceschi F., Hansen H., Bartels H., Zarivach R., et al. Structural basis for the antibiotic activity of ketolides and azalides. Structure 11 (2003) 329-338
21. BK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 121 (2005) 257-270
22. Petropoulos A.D., Kouvela E.C., Starosta A.L., Wilson D.N., Dinos G.P., and Kalpalxis D.L. Time-resolved binding of azithromycin to Escherichia coli ribosomes. J Mol Biol 385 (2009) 1179-1192